ATE162718T1 - Verwendung von prostacyclin-derivaten zur verhinderung oder behandlung von störungen der mikrozirkulation bei gabe von röntgen-, nmr- oder ultraschallkontrastmitteln - Google Patents

Verwendung von prostacyclin-derivaten zur verhinderung oder behandlung von störungen der mikrozirkulation bei gabe von röntgen-, nmr- oder ultraschallkontrastmitteln

Info

Publication number
ATE162718T1
ATE162718T1 AT92922216T AT92922216T ATE162718T1 AT E162718 T1 ATE162718 T1 AT E162718T1 AT 92922216 T AT92922216 T AT 92922216T AT 92922216 T AT92922216 T AT 92922216T AT E162718 T1 ATE162718 T1 AT E162718T1
Authority
AT
Austria
Prior art keywords
ray
prevent
nmr
pct
contrast agents
Prior art date
Application number
AT92922216T
Other languages
German (de)
English (en)
Inventor
Rainer Klopp
Wolfgang Niemer
Wolfgang Schippel
Werner Krause
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of ATE162718T1 publication Critical patent/ATE162718T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
AT92922216T 1991-10-22 1992-10-22 Verwendung von prostacyclin-derivaten zur verhinderung oder behandlung von störungen der mikrozirkulation bei gabe von röntgen-, nmr- oder ultraschallkontrastmitteln ATE162718T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4135193A DE4135193C1 (enExample) 1991-10-22 1991-10-22

Publications (1)

Publication Number Publication Date
ATE162718T1 true ATE162718T1 (de) 1998-02-15

Family

ID=6443371

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92922216T ATE162718T1 (de) 1991-10-22 1992-10-22 Verwendung von prostacyclin-derivaten zur verhinderung oder behandlung von störungen der mikrozirkulation bei gabe von röntgen-, nmr- oder ultraschallkontrastmitteln

Country Status (11)

Country Link
US (1) US5814301A (enExample)
EP (1) EP0609336B1 (enExample)
JP (1) JPH07500585A (enExample)
AT (1) ATE162718T1 (enExample)
CA (1) CA2121838A1 (enExample)
DE (2) DE4135193C1 (enExample)
DK (1) DK0609336T3 (enExample)
ES (1) ES2114570T3 (enExample)
GR (1) GR3026324T3 (enExample)
PT (1) PT100997B (enExample)
WO (1) WO1993007875A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
WO1997026862A2 (de) * 1996-01-25 1997-07-31 Schering Aktiengesellschaft Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung
ES2214753T3 (es) * 1997-11-14 2004-09-16 United Therapeutics Corporation Uso de 9-desoxi-2',9-alfa-metano-3-oxa-4,5,6-trinor-3,7-(1',3'-interfenilen)-13,14-dihidro-prostaglandina f1 para tratar la enfermedad vascular periferica.
CN1319011A (zh) * 1999-06-14 2001-10-24 东丽株式会社 药物在肿瘤组织蓄积的增强剂
US20020147223A1 (en) * 1999-06-14 2002-10-10 Hiroshi Maeda Agent for enhancing accumulation of drugs in tumor tissues
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
CN101780092B (zh) * 2003-05-22 2012-07-04 联合治疗公司 化合物和释放前列环素类似物的方法
DE602005020269D1 (de) * 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
CA2905720C (en) 2013-03-14 2021-10-19 United Therapeutics Corporation Solid forms of treprostinil
KR20210046018A (ko) * 2018-09-14 2021-04-27 파모사 바이오팜 인코포레이티드 약산성 약물의 방출 제어를 위한 약제학적 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2845770A1 (de) * 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
DE3204443A1 (de) * 1982-02-08 1983-08-18 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3448257C2 (en) * 1984-07-25 1988-08-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Cytoprotective action of prostacyclin derivatives on the kidney
US4820732A (en) * 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
US4955878A (en) * 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
SE459806B (sv) * 1987-11-23 1989-08-07 Nils Enar Nilsson Anordning foer foerflyttning av en foersta del relativt en andra del
DE3740838A1 (de) * 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
JPH0669966B2 (ja) * 1989-07-05 1994-09-07 株式会社ミドリ十字 血管造影補助剤

Also Published As

Publication number Publication date
CA2121838A1 (en) 1993-04-29
DE4135193C1 (enExample) 1993-03-11
DE59209175D1 (de) 1998-03-05
WO1993007875A1 (de) 1993-04-29
JPH07500585A (ja) 1995-01-19
PT100997A (pt) 1994-01-31
DK0609336T3 (da) 1998-09-21
EP0609336A1 (de) 1994-08-10
US5814301A (en) 1998-09-29
EP0609336B1 (de) 1998-01-28
GR3026324T3 (en) 1998-06-30
ES2114570T3 (es) 1998-06-01
PT100997B (pt) 1999-10-29

Similar Documents

Publication Publication Date Title
DE69104723D1 (de) Hustenstillendes und schleimregulierendes mittel, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
ATE246190T1 (de) Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
DE69429078D1 (de) Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
DK0641328T3 (da) Broforbundne, azabicykliske derivater som substans P-antagonister
NO306346B1 (no) N-substituerte azabicykloalkanderivater, anvendelse derav og farmasöytisk preparat
ATE162718T1 (de) Verwendung von prostacyclin-derivaten zur verhinderung oder behandlung von störungen der mikrozirkulation bei gabe von röntgen-, nmr- oder ultraschallkontrastmitteln
DE69632193D1 (de) Cyclooxygenaseinhibitor und salze von amidinderivaten, verfahren zu deren herstellung, deren verwendung als arzneiwirkstoffe sowie diese salze enthaltende arzneimittel
DK0738269T5 (da) Piperidinderivater med PAF-antagonistaktivitet
DK0572635T3 (da) Hidtil ukendte forbindelser med guanidinstruktur og farmaceutisk komposition indeholdende forbindelserne
NO306400B1 (no) N-substituerte azabicykloheptan-derivater, anvendelse derav og farmasöytisk preparat
DE59108744D1 (de) 8-EN-19, 11 beta-ÜBERBRÜCKTE STEROIDE, DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE
ES2094545T3 (es) Derivados n-substituidos del 3-azabiciclo(3.2.0)heptano, como neurolepticos etc..
AU3160995A (en) New 3-substituted 3h-2,3-benzodiazepine derivatives, their preparation and use as medicaments
NO950177L (no) Farmakologisk aktive erivater
ATE173471T1 (de) Pyridazinonderivate oder deren salze, verfahren zu ihrer herstellung und diese enthaltende antischockmittel
MX9205385A (es) Perhidro-1-h-pirido(1,2-a)piracinas 2-sustituidas neurolepticas.
IL105122A0 (en) Benzimidazole derivative for use as an anti-irritant
YU140491A (sh) 6-supstituisani-tetrahidrobenz(c,d) indoli
ATE144986T1 (de) Aminoacylderivate von gem- diphosphonsauren,verfahren zu deren herstellung und pharmazeutische zubereitungen,die sie enthalten
ATE150026T1 (de) Benzo(f>chinoxalindionderivative, deren herstellung und verwendung in arzneimitteln
ATE145647T1 (de) Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen
ATE195529T1 (de) 17beta-(2-oxo-tetrahydrofuran-4-yl)-thio- androstane derivate (17beta-(gamma-buttersäure- lacton)-thio derivate) zur behandlung von entzündungen, pharmazeutische präparate davon und ein verfahren zu ihrer herstellung
ATE141593T1 (de) Leukotrien-b 4?-derivative, verfahren zu ihrer herstellung und arzneimittel
DK0673377T3 (da) Nye triazoloquinazoliner, fremstilling og anvendelse deraf

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee